This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farokhzad, O. C. Articles by Langer, R. Search for Related Content PubMed PubMed Citation Articles by Farokhzad, O. C. Articles by Langer, R.

Nanoparticle-Aptamer Bioconjugates

A New Approach for Targeting Prostate Cancer Cells

¹ Department of Anesthesiology, Brigham and Women’s Hospital, Boston, Massachusetts; ² Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts; ³ Department of Life Science, Gwangju Institute of Science & Technology, Gwangju, South Korea; and ⁴ Division of Biological Engineering, ⁵ Department of Chemical Engineering, and ⁶ Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts

Nucleic acid ligands (aptamers) are potentially well suited for the therapeutic targeting of drug encapsulated controlled release polymer particles in a cell- or tissue-specific manner. We synthesized a bioconjugate composed of controlled release polymer nanoparticles and aptamers and examined its efficacy for targeted delivery to prostate cancer cells. Specifically, we synthesized poly(lactic acid)-block-polyethylene glycol (PEG) copolymer with a terminal carboxylic acid functional group (PLA-PEG-COOH), and encapsulated rhodamine-labeled dextran (as a model drug) within PLA-PEG-COOH nanoparticles. These nanoparticles have the following desirable characteristics: (a) negative surface charge (–50 ± 3 mV, mean ± SD, n = 3), which may minimize nonspecific interaction with the negatively charged nucleic acid aptamers; (b) carboxylic acid groups on the particle surface for potential modification and covalent conjugation to amine-modified aptamers; and (c) presence of PEG on particle surface, which enhances circulating half-life while contributing to decreased uptake in nontargeted cells. Next, we generated nanoparticle-aptamer bioconjugates with RNA aptamers that bind to the prostate-specific membrane antigen, a well-known prostate cancer tumor marker that is overexpressed on prostate acinar epithelial cells. We demonstrated that these bioconjugates can efficiently target and get taken up by the prostate LNCaP epithelial cells, which express the prostate-specific membrane antigen protein (77-fold increase in binding versus control, n = 150 cells per group). In contrast to LNCaP cells, the uptake of these particles is not enhanced in cells that do not express the prostate-specific membrane antigen protein. To our knowledge, this represents the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates.

This article has been cited by other articles:

				S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles PNAS, November 11, 2008; 105(45): 17356 - 17361. [Abstract] [Full Text] [PDF]

				B. Perlstein, Z. Ram, D. Daniels, A. Ocherashvilli, Y. Roth, S. Margel, and Y. Mardor Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring Neuro-oncol, April 1, 2008; 10(2): 153 - 161. [Abstract] [Full Text] [PDF]

				K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1310 - 1316. [Abstract] [Full Text] [PDF]

				F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, and O. C. Farokhzad From the Cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers PNAS, February 19, 2008; 105(7): 2586 - 2591. [Abstract] [Full Text] [PDF]

				K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells Cancer Res., July 1, 2007; 67(13): 6368 - 6375. [Abstract] [Full Text] [PDF]

				D. De Paula, M. V. L.B. Bentley, and R. I. Mahato Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting RNA, April 1, 2007; 13(4): 431 - 456. [Abstract] [Full Text] [PDF]

				J. Sun, C. DuFort, M.-C. Daniel, A. Murali, C. Chen, K. Gopinath, B. Stein, M. De, V. M. Rotello, A. Holzenburg, et al. Core-controlled polymorphism in virus-like particles PNAS, January 23, 2007; 104(4): 1354 - 1359. [Abstract] [Full Text] [PDF]

				D. S. Coffey, R. H. Getzenberg, and T. L. DeWeese Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". JAMA, July 26, 2006; 296(4): 445 - 448. [Full Text] [PDF]

				T. C. Chu, J. W. Marks III, L. A. Lavery, S. Faulkner, M. G. Rosenblum, A. D. Ellington, and M. Levy Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells. Cancer Res., June 15, 2006; 66(12): 5989 - 5992. [Abstract] [Full Text] [PDF]

				T. C. Chu, K. Y. Twu, A. D. Ellington, and M. Levy Aptamer mediated siRNA delivery Nucleic Acids Res., June 1, 2006; 34(10): e73 - e73. [Abstract] [Full Text] [PDF]

				O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo PNAS, April 18, 2006; 103(16): 6315 - 6320. [Abstract] [Full Text] [PDF]

				S. Fitter and R. James Deconvolution of a Complex Target Using DNA Aptamers J. Biol. Chem., October 7, 2005; 280(40): 34193 - 34201. [Abstract] [Full Text] [PDF]

				S. E. McNeil Nanotechnology for the biologist J. Leukoc. Biol., September 1, 2005; 78(3): 585 - 594. [Abstract] [Full Text] [PDF]

				R. Rossin, D. Pan, K. Qi, J. L. Turner, X. Sun, K. L. Wooley, and M. J. Welch 64Cu-Labeled Folate-Conjugated Shell Cross-Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation J. Nucl. Med., July 1, 2005; 46(7): 1210 - 1218. [Abstract] [Full Text] [PDF]